EA200800729A1 - Лечение неврита зрительного нерва - Google Patents

Лечение неврита зрительного нерва

Info

Publication number
EA200800729A1
EA200800729A1 EA200800729A EA200800729A EA200800729A1 EA 200800729 A1 EA200800729 A1 EA 200800729A1 EA 200800729 A EA200800729 A EA 200800729A EA 200800729 A EA200800729 A EA 200800729A EA 200800729 A1 EA200800729 A1 EA 200800729A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
patients
neveritis
present
beta protein
Prior art date
Application number
EA200800729A
Other languages
English (en)
Other versions
EA013816B1 (ru
Inventor
Роберт Серготт
Original Assignee
Арес Трейдинг С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Арес Трейдинг С.А. filed Critical Арес Трейдинг С.А.
Publication of EA200800729A1 publication Critical patent/EA200800729A1/ru
Publication of EA013816B1 publication Critical patent/EA013816B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к способу лечения больного демиелинизирующим невритом зрительного нерва (ДНЗН), предусматривающему последовательное или одновременное введение стероидного соединения и белка интерферона-бета. Обнаружено, что раннее активное лечение IFN-β полезно при таком режиме лечения, где, например, белок интерферона-бета вводят в совокупной недельной дозе более 12 ММЕ. Способ по изобретению особенно подходит для лечения пациентов на ранних стадиях ДНЗН и оказывает положительное влияние на этих больных. В частности, ДНЗН, при котором проявится положительное влияние лечения по настоящему изобретению, может находиться на субклинической стадии.
EA200800729A 2005-09-01 2006-08-30 Лечение неврита зрительного нерва EA013816B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71324605P 2005-09-01 2005-09-01
PCT/EP2006/065830 WO2007025991A2 (en) 2005-09-01 2006-08-30 Treatment of optic neuritis

Publications (2)

Publication Number Publication Date
EA200800729A1 true EA200800729A1 (ru) 2008-06-30
EA013816B1 EA013816B1 (ru) 2010-08-30

Family

ID=37478847

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800729A EA013816B1 (ru) 2005-09-01 2006-08-30 Лечение неврита зрительного нерва

Country Status (12)

Country Link
US (1) US8178083B2 (ru)
EP (1) EP1933860A2 (ru)
JP (1) JP2009507003A (ru)
KR (1) KR20080050591A (ru)
CN (1) CN101282740A (ru)
AU (1) AU2006286489B2 (ru)
BR (1) BRPI0616118A2 (ru)
CA (1) CA2616479A1 (ru)
EA (1) EA013816B1 (ru)
IL (1) IL189849A (ru)
WO (1) WO2007025991A2 (ru)
ZA (1) ZA200801923B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2685596A1 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
JP2014521659A (ja) * 2011-07-28 2014-08-28 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療
RU2494709C1 (ru) * 2012-05-16 2013-10-10 Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации Способ лечения острого неврита зрительного нерва

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982002715A1 (fr) * 1981-02-04 1982-08-19 Sugano Haruo Gene d'interferon (beta)humain
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) * 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
JPS62153300A (ja) 1985-12-26 1987-07-08 Teijin Ltd ヒト免疫グロブリンＧＦｃ領域蛋白質およびその製造方法
US4879111A (en) * 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4965195A (en) * 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
EP0325224B1 (en) * 1988-01-22 1996-07-31 ZymoGenetics, Inc. Methods of producing secreted receptor analogs
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
CA2100329C (en) 1991-01-18 2009-09-29 David F. Carmichael Methods for treating tumor necrosis factor mediated diseases
KR0155015B1 (ko) 1992-10-21 1998-12-01 고우야 마사시 2-아미노-1,3-프로판디올 화합물 및 면역 억제제
PT778263E (pt) 1994-08-22 2002-06-28 Mitsubishi Pharma Corp Composto de benzeno e sua utilizacao farmaceutica
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
EP0727406B1 (de) 1995-02-16 2001-09-05 MERCK PATENT GmbH Vinylenverbindungen und flüssigkristallines Medium
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
IL123887A0 (en) * 1997-04-02 1998-10-30 Sankyo Co Dithiolan derivatives their use and pharmaceutical compositions containing the same
FR2762514B1 (fr) 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
CN1187094C (zh) 1998-04-28 2005-02-02 应用研究系统Ars股份公司 多元醇干扰素β偶联物
TW591026B (en) 1998-06-23 2004-06-11 Upjohn Co Inhibitors of alpha4beta1 mediated cell adhesion
PL200586B1 (pl) * 1998-10-16 2009-01-30 Biogen Idec Inc Polipeptydy zawierające mutanty interferonu-beta-1a, kodujące je cząsteczki kwasów nukleinowych, komórki gospodarza transformowane tymi cząsteczkami, sposób wytwarzania polipeptydów, zawierające je kompozycje farmaceutyczne i zastosowania polipeptydów
NZ517184A (en) 1999-07-13 2004-02-27 Bolder Biotechnology Inc Immunoglobulin fusion proteins that are cytokines or growth factors joined to an Immunoglobulin domain
US20020115689A1 (en) 1999-12-21 2002-08-22 Joanne Waldstreicher Combination therapy for treating neurodegenerative disease
EP1110957A1 (en) 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
CA2421893A1 (en) 2000-08-31 2002-03-07 Merck And Co., Inc. Phosphate derivatives as immunoregulatory agents
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US6356036B1 (en) * 2000-12-01 2002-03-12 Laser Diagnostic Technologies, Inc. System and method for determining birefringence of anterior segment of a patient's eye
ATE314383T1 (de) 2001-03-26 2006-01-15 Novartis Pharma Gmbh 2-amino-propanol derivate
ATE396719T1 (de) 2001-04-05 2008-06-15 Aventis Pharma Inc Verwendung von (z)-2-cyano-3-hydroxy-but-2- ensäure-(4'-trifluoromethylphenyl)-amid zur behandlung der multiplen sklerose
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
GEP20063937B (en) 2002-02-14 2006-10-10 Pharmacia Corp Substituted pyridinones as modulators of p38 map kinase
GB0204159D0 (en) 2002-02-22 2002-04-10 British Biotech Pharm Metalloproteinase inhibitors
US7016048B2 (en) * 2002-04-09 2006-03-21 The Regents Of The University Of California Phase-resolved functional optical coherence tomography: simultaneous imaging of the stokes vectors, structure, blood flow velocity, standard deviation and birefringence in biological samples
KR20080103117A (ko) * 2002-09-24 2008-11-26 노파르티스 아게 탈수초성 장애의 치료에 있어서의 스핑고신-1-포스페이트 수용체 아고니스트
CN1684583A (zh) 2002-09-25 2005-10-19 明治制果株式会社 缓释农药颗粒剂
TWI291467B (en) 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor

Also Published As

Publication number Publication date
JP2009507003A (ja) 2009-02-19
WO2007025991A2 (en) 2007-03-08
IL189849A0 (en) 2008-11-03
EA013816B1 (ru) 2010-08-30
CN101282740A (zh) 2008-10-08
ZA200801923B (en) 2009-09-30
KR20080050591A (ko) 2008-06-09
WO2007025991A3 (en) 2007-05-10
AU2006286489B2 (en) 2012-08-09
US8178083B2 (en) 2012-05-15
EP1933860A2 (en) 2008-06-25
BRPI0616118A2 (pt) 2011-06-07
AU2006286489A1 (en) 2007-03-08
IL189849A (en) 2012-04-30
CA2616479A1 (en) 2007-03-08
US20080317711A1 (en) 2008-12-25

Similar Documents

Publication Publication Date Title
RU2007105354A (ru) Применение комбинации циклоспорина и пэгилированного интерферона для лечения гепатита с (hcv)
DE602004028841D1 (de) Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
BR0214772A (pt) sistemas e métodos para o tratamento de pacientes com células lipoaspiradas processadas
MXPA05006994A (es) Composiciones y metodos para la prevencion y el control de hipoglucemia inducida por insulina.
EP2583677A3 (en) Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
CA2353553A1 (en) Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia
BR0209114A (pt) Terapia de combinação usando agentes antiangiogênicos e tnfalfa
MX2021002147A (es) Tratamiento de la infección por virus de la hepatitis delta con interferón lambda.
DE60237721D1 (de) Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen
MX2022006742A (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter.
WO2003063780A3 (en) Therapeutic composition for treatment of cancer by arginine depletion
EA200800729A1 (ru) Лечение неврита зрительного нерва
BR112012020185A2 (pt) uso de preparações de heparina oral para tratar doenças e afecções do trato urinário.
EA200801731A1 (ru) Составы и способы лечения тробмоцитемии
WO2022079290A3 (en) Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
MD2549F1 (en) Method of treatment of the chronic viral hepatitis C
EA201101036A1 (ru) Применение хлорида аммония в терапии
RU2013120345A (ru) Новые способы лечения инфекции, вызванной вирусом гепатита с
RU2003113210A (ru) Лечение раковых заболеваний
JOP20190019A1 (ar) تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
RU2013129824A (ru) Новое лечение инфекции вируса гепатита с
TW200612981A (en) Treatment of cardiomyopathy and of endothelial dysfunction
WO2008021536A3 (en) Use of interferon tau for the manufacture of a medicament in combination with interferon-alpha or interferon-beta for reduction of their adverse effects
BR112022006913A2 (pt) Métodos para tratar infecções virais de hepatite delta
RU2013148539A (ru) Алиспоривир для лечения инфекции вируса гепатита с

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU